Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

Giuliani Jacopo; Bonetti Andrea

首页> 外文期刊>Clinical lung cancer >Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

【24h】

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

机译：酪氨酸激酶抑制剂在晚期非小细胞肺癌激活表皮生长因子受体突变的一线治疗中的药理费用：关键III期随机对照试验的审查。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Clinical lung cancer》 |2016年第2期|共4页
作者
Giuliani Jacopo; Bonetti Andrea;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Advanced NSCLC; Costs of drugs; First-line chemotherapy; Randomized phase III trials; Targeted therapies;

机译：晚期非小细胞肺癌;药物成本;一线化疗;随机化III期试验;靶向治疗;

相似文献

外文文献
中文文献
专利

1. Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials [J] . Giuliani Jacopo, Bonetti Andrea Clinical lung cancer . 2016,第2期

机译：酪氨酸激酶抑制剂在晚期非小细胞肺癌激活表皮生长因子受体突变的一线治疗中的药理费用：关键III期随机对照试验的审查。
2. Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials [J] . Giuliani Jacopo, Bonetti Andrea Clinical lung cancer . 2016,第2期

机译：酪氨酸激酶抑制剂在先进的非小细胞肺癌中激活表皮生长因子受体突变的药理学成本：术语III随机对照试验综述
3. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations [J] . Giuliani Jacopo, Remo Andrea, Bonetti Andrea Expert review of pharmacoeconomics & outcomes research . 2017,第1a3期

机译：欧洲医学肿瘤医学初级社会临床益处（ESMO-MCBS）在一线中施用酪氨酸激酶抑制剂的托源激酶抑制剂的枢转期III随机对照试验，其具有激活表皮生长因子受体突变的先进非小细胞肺癌
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [O] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, 2015

机译：吸烟状态在非小细胞肺癌患者无进展生存中的作用该患者具有接受一线EGFR酪氨酸激酶抑制剂对铂类双重化疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的Meta分析。
7. PCN40 The Impact Of First-Line Tyrosine Kinase Inhibitors (Tkis) On Overall Survival In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) And Activating Epidermal Growth Factor Receptor (Egfr) Mutations: Meta-Analysis Of Major Randomized Trials By Mutation Type [O] . Kato T, De Marinis F, Spicer J, 2015

机译：PCN40一线酪氨酸激酶抑制剂（Tkis）对晚期非小细胞肺癌（Nsclc）和活化表皮生长因子受体（Egfr）突变患者总体生存的影响：按突变类型对主要随机试验进行荟萃分析

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

著录项

引文网络

相似文献

相关主题

期刊订阅